EAU guidelines on renal cell carcinoma: The 2010 update

European Urology

Volumn 58, Issue 3, 2010, Pages 398-406

  Ljungberg, Börje ^a   Cowan, Nigel C ^b   Hanbury, Damian C ^c   Hora, Milan ^d   Kuczyk, Markus A ^e   Merseburger, Axel S ^e   Patard, Jean Jacques ^f   Mulders, Peter F A ^g   Sinescu, Ioanel C ^h  

^a UMEÅ UNIVERSITY   (Sweden)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c LISTER HOSPITAL   (United Kingdom)

^d CHARLES UNIVERSITY   (Czech Republic)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f BICÊTRE HOSPITAL   (France)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

Diagnosis; Follow up; Guidelines; Recommendations; Renal cell carcinoma; Treatment

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; BEVACIZUMAB; C REACTIVE PROTEIN; CALCIUM; CREATININE; EVEROLIMUS; HEMOGLOBIN; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADRENALECTOMY; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTIFICIAL EMBOLISM; BONE PAIN; CALCIUM BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL PRACTICE; COCHRANE LIBRARY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CRYOABLATION; DISEASE SURVEILLANCE; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED PRACTICE; FLANK PAIN; GLOMERULUS FILTRATION RATE; HEMATURIA; HIGH INTENSITY FOCUSED ULTRASOUND; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY FUNCTION; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; MEDICAL LITERATURE; MEDLINE; METASTASIS; MULTICENTER STUDY; NEPHRECTOMY; NEPHRON SPARING SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLICATION; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; REVIEW; TREATMENT INDICATION; VALIDATION STUDY;

EID: 77955493600     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.06.032     Document Type: Article

References (50)

1. B. Ljungberg, D.C. Hanbury, and M.A. Kuczyk Renal cell carcinoma guideline Eur Urol 51 2007 1502 1510
2. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 2010 765 781
3. F. Levi, J. Ferlay, and C. Galeone The changing pattern of kidney cancer incidence and mortality in Europe BJU Int 101 2008 949 958 (Pubitemid 351422561)
4. J.D. Hunt, O.L. van der Hel, and G.P. McMillan Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies Int J Cancer 114 2005 101 108
5. T. Pischon, P.H. Lahmann, and H. Boeing Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC) Int J Cancer 118 2006 728 738 (Pubitemid 43076024)
6. S. Weikert, H. Boeing, and T. Pischon Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition Am J Epidemiol 167 2008 438 446 (Pubitemid 351264143)
7. J. Clague, J. Lin, and A. Cassidy Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis Cancer Epidemiol Biomarkers Prev 18 2009 801 807
8. J. Sanz-Ortega, C. Olivier, P. Perez Segura, I. Galante Romo, L. San Jose Manso, and M. Saez Hereditary renal cancer Actas Urol Esp 33 2009 127 133
9. J.-J. Patard, E. Leray, A. Rodriguez, N. Rioux-Leclercq, F. Guillé, and B. Lobel Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma Eur Urol 44 2003 226 232
10. R.J. Motzer, J. Bacik, B.A. Murphy, P. Russo, and M. Mazumdar Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296
11. G.M. Israel, and M.A. Bosniak Pitfalls in renal mass evaluation and how to avoid them Radiographics 28 2008 1325 1338
12. K.S. Warren, and J. McFarlane The Bosniak classification of renal cystic masses BJU Int 95 2005 939 942
13. L.G. Putra, T.X. Minor, D.M. Bolton, S. Appu, C.R. Dowling, and G.J. Neerhut Improved assessment of renal lesions in pregnancy with magnetic resonance imaging Urology 74 2009 535 539
14. J.W. Park, M.K. Jo, and H.M. Lee Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma BJU Int 103 2009 615 619
15. B.A. Shannon, R.J. Cohen, H. de Bruto, and R.J. Davies The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses J Urol 180 2008 1257 1261 discussion 1261
16. M. Remzi, and M. Marberger Renal tumor biopsies for evaluation of small renal tumors: why, in whom and how? Eur Urol 55 2009 359 367
17. J.N. Eble, G. Sauter, J.I. Epstein, I.A. Sesterhenn, Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours 2004 IARC Press Lyon, France 7
18. G. Pignot, C. Elie, and S. Conquy Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification Urology 69 2007 230 235
19. L.H. Sobin, M. Gospodariwicz, C. Wittekind, TNM classification of malignant tumors. UICC International Union Against Cancer 7th ed. 2009 Wiley-Blackwell New York 255 257
20. U. Capitanio, V. Cloutier, and L. Zini A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study BJU Int 103 2009 1496 1500
21. K.A. Furge, M.H. Tan, and K. Dykema Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling Oncogene 26 2007 1346 1350
22. M. Sabatino, S. Kim-Schulze, and M.C. Panelli Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy J Clin Oncol 27 2009 2645 2652
23. R. Zigeuner, G. Hutterer, and T. Chromecki External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology Eur Urol 57 2010 102 111
24. J. Ramon, U. Rimon, and A. Garniek Renal angiomyolipoma: long-term results following selective arterial embolization Eur Urol 55 2009 1155 1162
25. M. Peycelon, V. Hupertan, and E. Comperat Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm J Urol 181 2009 35 41
26. J.H. Luo, F.J. Zhou, and D. Xie Analysis of long-term survival in patients with localized renal cell carcinoma: laparoscopic versus open radical nephrectomy World J Urol 28 2010 289 293
27. B.R. Lane, H.Y. Tiong, and S.C. Campbell Management of the adrenal gland during partial nephrectomy J Urol 181 2009 2430 2436 discussion 2436-7
28. J.H.M. Blom, H. van Poppel, J.M. Maréchal EORTC Genitourinary Tract Cancer Group Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881 Eur Urol 55 2009 28 34
29. C.J. Weight, B.T. Larson, and A.F. Fergany Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses J Urol 183 2010 1317 1323
30. M.N. Simmons, C.J. Weight, and I.S. Gill Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes Urology 73 2009 1077 1082
31. G. Pasticier, M.-O. Timsit, and L. Badet Nephron-sparing surgery for renal cell carcinoma: detailed analysis of complications over a 15-year period Eur Urol 49 2006 485 490
32. K. Bensalah, A.J. Pantuck, and N. Rioux-Leclercq Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery Eur Urol 57 2010 466 473
33. N.A. Burgess, B.C. Koo, R.C. Calvert, A. Hindmarsh, P.J. Donaldson, and M. Rhodes Randomized trial of laparoscopic v open nephrectomy J Endourol 21 2007 610 613
34. G. Godoy, V. Ramanathan, and J.A. Kanofsky Effect of warm ischemia time during laparoscopic partial nephrectomy on early postoperative glomerular filtration rate J Urol 181 2009 2438 2443
35. M. May, S. Brookman-Amissah, S. Pflanz, J. Roigas, B. Hoschke, and F. Kendel Preoperative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma Br J Radiol 82 2009 724 731
36. A.R. Forauer, E. Kent, W. Cwikiel, P. Esper, and B. Redman Selective palliative transcatheter embolization of bony metastases from renal cell carcinoma Acta Oncol 46 2007 1012 1018
37. S. Rais-Bahrami, T.J. Guzzo, T.W. Jarrett, L.R. Kavoussi, and M.E. Allaf Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention BJU Int 103 2009 1355 1358
38. D.A. Kunkle, and R.G. Uzzo Cryoablation or radiofrequency ablation of the small renal mass: a metaanalysis Cancer 113 2008 2671 2680
39. R.C. Flanigan, G. Mickisch, R. Sylvester, C. Tangen, H. Van Poppel, and E.D. Crawford Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 171 2004 1071 1076
40. H.G. van der Poel, J.A. Roukema, S. Horenblas, A.N. van Geel, and F.M. Debruyne Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis Eur Urol 35 1999 197 203
41. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005:CD001425.
42. J.-J. Patard, N. Rioux-Leclercq, and P. Fergelot Understanding the importance of smart drugs in renal cell carcinoma Eur Urol 49 2006 633 643
43. B. Escudier, T. Eisen, W.M. Stadler TARGET Study Group Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
44. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
45. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
46. B. Escudier, A. Pluzanska, P. Koralewski AVOREN Trial Investigators Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
47. G. Hudes, M. Carducci, P. Tomczak Global ARCC Trial Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281 (Pubitemid 46849157)
48. R.J. Motzer, B. Escudier, S. Oudard RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
49. J.S. Lam, O. Shvarts, J.T. Leppert, R.A. Figlin, and A.S. Belldegrun Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy J Urol 173 2005 1853 1862
50. L. Cindolo, J.J. Patard, and P. Chiodini Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study Cancer 104 2005 1362 1371